{"success":true,"data":{"pressRelease":{"id":"104640","rtpr_id":"nPred7zTXa","ticker":"AMGN","exchange":"NASDAQ","all_tickers":["AMGN"],"title":"FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD","author":"PR Newswire","published_at":"2026-07-31T06:04:40.336Z","article_body":"FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD\nPR Newswire\n\nHYDERABAD, India, July 31, 2026\n\nTwo-Year Commitment will Inspire the Next Generation of Scientific Innovators\nThrough AI-Enabled Research in Healthcare and Drug Discovery\n\nHYDERABAD, India, July 31, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today\nannounced the launch of the first Amgen Scholars Program in India at the\nInternational Institute of Information Technology Hyderabad (IIIT Hyderabad),\nbringing the globally respected undergraduate summer research program to India\nfor the first time.\n\n\n\nSupported through a two-year commitment from Amgen through summer 2027, the\nprogram reflects the company's long-standing commitment to advancing science\neducation and inspiring future innovators. The inaugural cohort comprises 10\nundergraduate scholars, including students from India, Vietnam, Qatar, and\nDubai, creating opportunities for scientific collaboration and exchange across\nAsia. The students represent universities across Asia and are pursuing\nundergraduate programs in science, engineering, and related disciplines,\nreflecting the program's regional diversity and academic excellence.\n\nAs part of the intensive two-month residential research experience, students\nwill explore artificial intelligence and machine learning applications in\nfundamental sciences, drug design and discovery, healthcare, cheminformatics,\ngenomics and related areas alongside faculty mentors at IIIT Hyderabad. They\nwill also have an opportunity to participate in seminars, networking events\nand a regional Amgen Scholars Symposium to be held in Tokyo in August 2026. At\nthe conclusion of the program, each scholar presents their research through a\nscientific poster presentation. The scholars were selected through a rigorous\nevaluation by an expert committee at IIIT Hyderabad based on academic\nexcellence, research aptitude, motivation for doctoral studies, and\ndemonstrated interest in applying AI and machine learning to drug discovery.\n\n\"Scientific breakthroughs begin with curious minds and meaningful\nopportunities to learn,\" said Naveen Gullapalli, Managing Director, Amgen\nIndia. \"We are proud to bring the Amgen Scholars Program to India. We hope to\ninspire talented students to pursue research careers while helping build the\ninterdisciplinary skills needed to strengthen India's scientific ecosystem.\"\n\n\"We are delighted to serve as the host institution for the first Amgen\nScholars Program in India,\" said Deva Priyakumar, Professor & Dean (R&D), IIIT\nHyderabad. \"The program aligns well with our research-led approach to\neducation and provides undergraduate students with an exceptional opportunity\nto contribute to cutting-edge research in AI for healthcare and drug discovery\nwhile learning from leading faculty.\"\n\n\"AI is transforming every stage of biotech research, from understanding\ndisease biology to discovering new medicines,\" said Sandeep Shukla, Professor\n& Director, IIIT Hyderabad. \"This program gives students an opportunity to\nwork on real scientific problems while developing the interdisciplinary\nresearch skills needed to address tomorrow's complex healthcare challenges.\"\n\nDesigned to inspire the scientists of tomorrow, the Amgen Scholars Program\n(https://www.amgenfoundation.org/science-education/amgen-scholars-program) is\na long-standing, signature initiative of the Amgen Foundation, providing\nundergraduates the opportunity to engage in a compelling summer, scientific\nresearch experience at some of the world's leading institutions. This program\nbuilds on successful programming in the United States, with over 4,000 U.S.\nstudents having benefited from the program. Twenty-six leading institutions\nacross the world currently host the summer research program. More than 6,000\nstudents from over 1,000 colleges and universities have participated to date.\nFinancial support for students is a critical component of the program, which\nseeks to ensure that eligible students, regardless of their financial status,\ncan participate. The Amgen Scholars Program seeks to expand research,\nlearning and networking opportunities for students committed to pursuing\nadvanced degrees in STEM. Thousands of program alumni have gone on to complete\ngraduate education and build careers across academia, biotechnology and\nhealthcare in more than 40 countries. www.amgenscholars.com. \n\nAbout Amgen \n\nAmgen discovers, develops, manufactures and delivers innovative medicines to\nfight some of the world's toughest diseases. Harnessing the best of biology\nand technology, Amgen reaches millions of patients with its medicines.\n\nMore than 45 years ago, Amgen helped establish the biotechnology industry at\nits U.S. headquarters in Thousand Oaks, California, and it remains at the\ncutting edge of innovation, using technology and human genetic data to push\nbeyond what is known today. Amgen is advancing a broad and deep pipeline and\nportfolio of medicines to treat cancer, heart disease, inflammatory\nconditions, rare diseases and obesity and obesity-related conditions.\n\nAmgen has been consistently recognized\n(https://wwwext.amgen.com/about/awards-and-accolades) for innovation and\nworkplace culture, including honors from Fast Company and Forbes. Amgen is one\nof the 30 companies that comprise the Dow Jones Industrial Average(®), and it\nis also part of the Nasdaq-100 Index(®), which includes the largest and most\ninnovative non-financial companies listed on the Nasdaq Stock Market based on\nmarket capitalization.\n\nFor more information, visit Amgen.com (http://www.amgen.com/) and follow\nAmgen on X (https://x.com/Amgen), LinkedIn\n(https://www.linkedin.com/company/amgen), Instagram\n(https://www.instagram.com/amgenbiotech/), YouTube\n(https://www.youtube.com/user/Amgen), Facebook\n(https://www.facebook.com/amgenbiotech/), TikTok\n(https://www.tiktok.com/@amgenbiotech) and Threads\n(https://www.threads.net/@amgenbiotech).\n\nFor more information about the Amgen Foundation, visit www.amgenfoundation.org\n\nAbout IIIT Hyderabad\n\nThe International Institute of Information Technology, Hyderabad (IIIT-H) is\nan autonomous research university founded in 1998 that focuses on the core\nareas of Information Technology, such as Computer Science, Electronics and\nCommunications, and their applications in other domains through\ninter-disciplinary research that has a greater social impact. Some of its\nresearch domains include Technology Innovation, Intelligent Systems, Signal\nProcessing and Communications, Data Sciences, Language Technologies,\nRobotics, Security, Algorithms, Software Engineering, Visual Information\nTechnology, VLSI and Embedded Systems Technology , Computer Systems, Machine\nLearning, Quantum Science and Technology, Computational Social Science,\nCognitive Science, Computational Natural Sciences and Bioinformatics,\nEarthquake Engineering, Human Sciences, Spatial Informatics, Innovation and\nEntrepreneurship, Smart Cities, Artificial Intelligence, Digital Technologies\nin Healthcare and Biomedical Research. \n\nWebsite: www.iiit.ac.in\n\nAmgen Forward-Looking Statements\n\nThis news release contains forward-looking statements that are based on the\ncurrent expectations and beliefs of Amgen. All statements, other than\nstatements of historical fact, are statements that could be deemed\nforward-looking statements, including any statements on the outcome, benefits\nand synergies of collaborations, or potential collaborations, with any other\ncompany (including BeOne Medicines Ltd.), the performance of Otezla®\n(apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics,\nLtd. or Horizon Therapeutics plc (including the prospective performance and\noutlook of Horizon's business, performance and opportunities, and any\npotential strategic benefits, synergies or opportunities expected as a result\nof such acquisition), as well as estimates of revenues, operating margins,\ncapital expenditures, cash, other financial metrics, expected legal,\narbitration, political, regulatory or clinical results or practices, customer\nand prescriber patterns or practices, reimbursement activities and outcomes,\neffects of pandemics or other widespread health problems on our business,\noutcomes, progress, and other such estimates and results. Forward-looking\nstatements involve significant risks and uncertainties, including those\ndiscussed below and more fully described in the Securities and Exchange\nCommission reports filed by Amgen, including our most recent annual report on\nForm 10-K and any subsequent periodic reports on Form 10-Q and current reports\non Form 8-K. Unless otherwise noted, Amgen is providing this information as of\nthe date of this news release and does not undertake any obligation to update\nany forward-looking statements contained in this document as a result of new\ninformation, future events or otherwise.\n\nNo forward-looking statement can be guaranteed, and actual results may differ\nmaterially from those we project. Our results may be affected by our ability\nto successfully market both new and existing products domestically and\ninternationally, clinical and regulatory developments involving current and\nfuture products, sales growth of recently launched products, competition from\nother products including biosimilars, difficulties or delays in manufacturing\nour products and global economic conditions, including those resulting from\ngeopolitical relations and government actions. In addition, sales of our\nproducts are affected by pricing pressure, political and public scrutiny and\nreimbursement policies imposed by third-party payers, including governments,\nprivate insurance plans and managed care providers and may be affected by\nregulatory, clinical and guideline developments and domestic and international\ntrends toward managed care and healthcare cost containment. Furthermore, our\nresearch, testing, pricing, marketing and other operations are subject to\nextensive regulation by domestic and foreign government regulatory\nauthorities. We or others could identify safety, side effects or manufacturing\nproblems with our products, including our devices, after they are on the\nmarket. Our business may be impacted by government investigations, litigation\nand product liability claims. In addition, our business may be impacted by the\nadoption of new tax legislation or exposure to additional tax liabilities.\nFurther, while we routinely obtain patents for our products and technology,\nthe protection offered by our patents and patent applications may be\nchallenged, invalidated or circumvented by our competitors, or we may fail to\nprevail in present and future intellectual property litigation. We perform a\nsubstantial amount of our commercial manufacturing activities at a few key\nfacilities, including Puerto Rico, and also depend on third parties for a\nportion of our manufacturing activities, and limits on supply may constrain\nsales of certain of our current products and product candidate development. An\noutbreak of disease or similar public health threat, and the public and\ngovernmental effort to mitigate against the spread of such disease, could have\na significant adverse effect on the supply of materials for our manufacturing\nactivities, the distribution of our products, the commercialization of our\nproduct candidates, and our clinical trial operations, and any such events may\nhave a material adverse effect on our product development, product sales,\nbusiness and results of operations. We rely on collaborations with third\nparties for the development of some of our product candidates and for the\ncommercialization and sales of some of our commercial products. In addition,\nwe compete with other companies with respect to many of our marketed products\nas well as for the discovery and development of new products. Discovery or\nidentification of new product candidates or development of new indications for\nexisting products cannot be guaranteed and movement from concept to product is\nuncertain; consequently, there can be no guarantee that any particular product\ncandidate or development of a new indication for an existing product will be\nsuccessful and become a commercial product. Further, some raw materials,\nmedical devices and component parts for our products are supplied by sole\nthird-party suppliers. Certain of our distributors, customers and payers have\nsubstantial purchasing leverage in their dealings with us. The discovery of\nsignificant problems with a product similar to one of our products that\nimplicate an entire class of products could have a material adverse effect on\nsales of the affected products and on our business and results of operations.\nOur efforts to collaborate with or acquire other companies, products or\ntechnology, and to integrate the operations of companies or to support the\nproducts or technology we have acquired, may not be successful, and may result\nin unanticipated costs, delays or failures to realize the benefits of the\ntransactions. A breakdown, cyberattack or information security breach of our\ninformation technology systems could compromise the confidentiality, integrity\nand availability of our systems and our data. Our stock price is volatile and\nmay be affected by a number of events. Our business and operations may be\nnegatively affected by the failure, or perceived failure, of achieving our\nsustainability objectives. The effects of global climate change and related\nnatural disasters could negatively affect our business and operations. Global\neconomic conditions may magnify certain risks that affect our business. Our\nbusiness performance could affect or limit the ability of our Board of\nDirectors to declare a dividend or our ability to pay a dividend or repurchase\nour common stock. We may not be able to access the capital and credit markets\non terms that are favorable to us, or at all.\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/in/news-releases/first-amgen-scholars-program-in-india-launches-at-iiit-hyderabad-302839774.html\n\n\n\nMedia Contact: Amgen India, Hyderabad | Anumita Tripathi | +91-9967160337 (Corporate Affairs)\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1961828/amgen_logo.jpg?id=OA2818790\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPred7zTXa","title":"FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD","author":"PR Newswire","ticker":"AMGN","created":"2026-07-31T06:04:40.336Z","tickers":["AMGN"],"exchange":"NASDAQ","article_body":"FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD\nPR Newswire\n\nHYDERABAD, India, July 31, 2026\n\nTwo-Year Commitment will Inspire the Next Generation of Scientific Innovators\nThrough AI-Enabled Research in Healthcare and Drug Discovery\n\nHYDERABAD, India, July 31, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today\nannounced the launch of the first Amgen Scholars Program in India at the\nInternational Institute of Information Technology Hyderabad (IIIT Hyderabad),\nbringing the globally respected undergraduate summer research program to India\nfor the first time.\n\n\n\nSupported through a two-year commitment from Amgen through summer 2027, the\nprogram reflects the company's long-standing commitment to advancing science\neducation and inspiring future innovators. The inaugural cohort comprises 10\nundergraduate scholars, including students from India, Vietnam, Qatar, and\nDubai, creating opportunities for scientific collaboration and exchange across\nAsia. The students represent universities across Asia and are pursuing\nundergraduate programs in science, engineering, and related disciplines,\nreflecting the program's regional diversity and academic excellence.\n\nAs part of the intensive two-month residential research experience, students\nwill explore artificial intelligence and machine learning applications in\nfundamental sciences, drug design and discovery, healthcare, cheminformatics,\ngenomics and related areas alongside faculty mentors at IIIT Hyderabad. They\nwill also have an opportunity to participate in seminars, networking events\nand a regional Amgen Scholars Symposium to be held in Tokyo in August 2026. At\nthe conclusion of the program, each scholar presents their research through a\nscientific poster presentation. The scholars were selected through a rigorous\nevaluation by an expert committee at IIIT Hyderabad based on academic\nexcellence, research aptitude, motivation for doctoral studies, and\ndemonstrated interest in applying AI and machine learning to drug discovery.\n\n\"Scientific breakthroughs begin with curious minds and meaningful\nopportunities to learn,\" said Naveen Gullapalli, Managing Director, Amgen\nIndia. \"We are proud to bring the Amgen Scholars Program to India. We hope to\ninspire talented students to pursue research careers while helping build the\ninterdisciplinary skills needed to strengthen India's scientific ecosystem.\"\n\n\"We are delighted to serve as the host institution for the first Amgen\nScholars Program in India,\" said Deva Priyakumar, Professor & Dean (R&D), IIIT\nHyderabad. \"The program aligns well with our research-led approach to\neducation and provides undergraduate students with an exceptional opportunity\nto contribute to cutting-edge research in AI for healthcare and drug discovery\nwhile learning from leading faculty.\"\n\n\"AI is transforming every stage of biotech research, from understanding\ndisease biology to discovering new medicines,\" said Sandeep Shukla, Professor\n& Director, IIIT Hyderabad. \"This program gives students an opportunity to\nwork on real scientific problems while developing the interdisciplinary\nresearch skills needed to address tomorrow's complex healthcare challenges.\"\n\nDesigned to inspire the scientists of tomorrow, the Amgen Scholars Program\n(https://www.amgenfoundation.org/science-education/amgen-scholars-program) is\na long-standing, signature initiative of the Amgen Foundation, providing\nundergraduates the opportunity to engage in a compelling summer, scientific\nresearch experience at some of the world's leading institutions. This program\nbuilds on successful programming in the United States, with over 4,000 U.S.\nstudents having benefited from the program. Twenty-six leading institutions\nacross the world currently host the summer research program. More than 6,000\nstudents from over 1,000 colleges and universities have participated to date.\nFinancial support for students is a critical component of the program, which\nseeks to ensure that eligible students, regardless of their financial status,\ncan participate. The Amgen Scholars Program seeks to expand research,\nlearning and networking opportunities for students committed to pursuing\nadvanced degrees in STEM. Thousands of program alumni have gone on to complete\ngraduate education and build careers across academia, biotechnology and\nhealthcare in more than 40 countries. www.amgenscholars.com. \n\nAbout Amgen \n\nAmgen discovers, develops, manufactures and delivers innovative medicines to\nfight some of the world's toughest diseases. Harnessing the best of biology\nand technology, Amgen reaches millions of patients with its medicines.\n\nMore than 45 years ago, Amgen helped establish the biotechnology industry at\nits U.S. headquarters in Thousand Oaks, California, and it remains at the\ncutting edge of innovation, using technology and human genetic data to push\nbeyond what is known today. Amgen is advancing a broad and deep pipeline and\nportfolio of medicines to treat cancer, heart disease, inflammatory\nconditions, rare diseases and obesity and obesity-related conditions.\n\nAmgen has been consistently recognized\n(https://wwwext.amgen.com/about/awards-and-accolades) for innovation and\nworkplace culture, including honors from Fast Company and Forbes. Amgen is one\nof the 30 companies that comprise the Dow Jones Industrial Average(®), and it\nis also part of the Nasdaq-100 Index(®), which includes the largest and most\ninnovative non-financial companies listed on the Nasdaq Stock Market based on\nmarket capitalization.\n\nFor more information, visit Amgen.com (http://www.amgen.com/) and follow\nAmgen on X (https://x.com/Amgen), LinkedIn\n(https://www.linkedin.com/company/amgen), Instagram\n(https://www.instagram.com/amgenbiotech/), YouTube\n(https://www.youtube.com/user/Amgen), Facebook\n(https://www.facebook.com/amgenbiotech/), TikTok\n(https://www.tiktok.com/@amgenbiotech) and Threads\n(https://www.threads.net/@amgenbiotech).\n\nFor more information about the Amgen Foundation, visit www.amgenfoundation.org\n\nAbout IIIT Hyderabad\n\nThe International Institute of Information Technology, Hyderabad (IIIT-H) is\nan autonomous research university founded in 1998 that focuses on the core\nareas of Information Technology, such as Computer Science, Electronics and\nCommunications, and their applications in other domains through\ninter-disciplinary research that has a greater social impact. Some of its\nresearch domains include Technology Innovation, Intelligent Systems, Signal\nProcessing and Communications, Data Sciences, Language Technologies,\nRobotics, Security, Algorithms, Software Engineering, Visual Information\nTechnology, VLSI and Embedded Systems Technology , Computer Systems, Machine\nLearning, Quantum Science and Technology, Computational Social Science,\nCognitive Science, Computational Natural Sciences and Bioinformatics,\nEarthquake Engineering, Human Sciences, Spatial Informatics, Innovation and\nEntrepreneurship, Smart Cities, Artificial Intelligence, Digital Technologies\nin Healthcare and Biomedical Research. \n\nWebsite: www.iiit.ac.in\n\nAmgen Forward-Looking Statements\n\nThis news release contains forward-looking statements that are based on the\ncurrent expectations and beliefs of Amgen. All statements, other than\nstatements of historical fact, are statements that could be deemed\nforward-looking statements, including any statements on the outcome, benefits\nand synergies of collaborations, or potential collaborations, with any other\ncompany (including BeOne Medicines Ltd.), the performance of Otezla®\n(apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics,\nLtd. or Horizon Therapeutics plc (including the prospective performance and\noutlook of Horizon's business, performance and opportunities, and any\npotential strategic benefits, synergies or opportunities expected as a result\nof such acquisition), as well as estimates of revenues, operating margins,\ncapital expenditures, cash, other financial metrics, expected legal,\narbitration, political, regulatory or clinical results or practices, customer\nand prescriber patterns or practices, reimbursement activities and outcomes,\neffects of pandemics or other widespread health problems on our business,\noutcomes, progress, and other such estimates and results. Forward-looking\nstatements involve significant risks and uncertainties, including those\ndiscussed below and more fully described in the Securities and Exchange\nCommission reports filed by Amgen, including our most recent annual report on\nForm 10-K and any subsequent periodic reports on Form 10-Q and current reports\non Form 8-K. Unless otherwise noted, Amgen is providing this information as of\nthe date of this news release and does not undertake any obligation to update\nany forward-looking statements contained in this document as a result of new\ninformation, future events or otherwise.\n\nNo forward-looking statement can be guaranteed, and actual results may differ\nmaterially from those we project. Our results may be affected by our ability\nto successfully market both new and existing products domestically and\ninternationally, clinical and regulatory developments involving current and\nfuture products, sales growth of recently launched products, competition from\nother products including biosimilars, difficulties or delays in manufacturing\nour products and global economic conditions, including those resulting from\ngeopolitical relations and government actions. In addition, sales of our\nproducts are affected by pricing pressure, political and public scrutiny and\nreimbursement policies imposed by third-party payers, including governments,\nprivate insurance plans and managed care providers and may be affected by\nregulatory, clinical and guideline developments and domestic and international\ntrends toward managed care and healthcare cost containment. Furthermore, our\nresearch, testing, pricing, marketing and other operations are subject to\nextensive regulation by domestic and foreign government regulatory\nauthorities. We or others could identify safety, side effects or manufacturing\nproblems with our products, including our devices, after they are on the\nmarket. Our business may be impacted by government investigations, litigation\nand product liability claims. In addition, our business may be impacted by the\nadoption of new tax legislation or exposure to additional tax liabilities.\nFurther, while we routinely obtain patents for our products and technology,\nthe protection offered by our patents and patent applications may be\nchallenged, invalidated or circumvented by our competitors, or we may fail to\nprevail in present and future intellectual property litigation. We perform a\nsubstantial amount of our commercial manufacturing activities at a few key\nfacilities, including Puerto Rico, and also depend on third parties for a\nportion of our manufacturing activities, and limits on supply may constrain\nsales of certain of our current products and product candidate development. An\noutbreak of disease or similar public health threat, and the public and\ngovernmental effort to mitigate against the spread of such disease, could have\na significant adverse effect on the supply of materials for our manufacturing\nactivities, the distribution of our products, the commercialization of our\nproduct candidates, and our clinical trial operations, and any such events may\nhave a material adverse effect on our product development, product sales,\nbusiness and results of operations. We rely on collaborations with third\nparties for the development of some of our product candidates and for the\ncommercialization and sales of some of our commercial products. In addition,\nwe compete with other companies with respect to many of our marketed products\nas well as for the discovery and development of new products. Discovery or\nidentification of new product candidates or development of new indications for\nexisting products cannot be guaranteed and movement from concept to product is\nuncertain; consequently, there can be no guarantee that any particular product\ncandidate or development of a new indication for an existing product will be\nsuccessful and become a commercial product. Further, some raw materials,\nmedical devices and component parts for our products are supplied by sole\nthird-party suppliers. Certain of our distributors, customers and payers have\nsubstantial purchasing leverage in their dealings with us. The discovery of\nsignificant problems with a product similar to one of our products that\nimplicate an entire class of products could have a material adverse effect on\nsales of the affected products and on our business and results of operations.\nOur efforts to collaborate with or acquire other companies, products or\ntechnology, and to integrate the operations of companies or to support the\nproducts or technology we have acquired, may not be successful, and may result\nin unanticipated costs, delays or failures to realize the benefits of the\ntransactions. A breakdown, cyberattack or information security breach of our\ninformation technology systems could compromise the confidentiality, integrity\nand availability of our systems and our data. Our stock price is volatile and\nmay be affected by a number of events. Our business and operations may be\nnegatively affected by the failure, or perceived failure, of achieving our\nsustainability objectives. The effects of global climate change and related\nnatural disasters could negatively affect our business and operations. Global\neconomic conditions may magnify certain risks that affect our business. Our\nbusiness performance could affect or limit the ability of our Board of\nDirectors to declare a dividend or our ability to pay a dividend or repurchase\nour common stock. We may not be able to access the capital and credit markets\non terms that are favorable to us, or at all.\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/in/news-releases/first-amgen-scholars-program-in-india-launches-at-iiit-hyderabad-302839774.html\n\n\n\nMedia Contact: Amgen India, Hyderabad | Anumita Tripathi | +91-9967160337 (Corporate Affairs)\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1961828/amgen_logo.jpg?id=OA2818790\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-31T06:04:40.38309837Z","server_sent_at_ms":1785477880383},"received_at":"2026-07-31T06:04:40.532Z","source_url":"https://www.prnewswire.com/in/news-releases/first-amgen-scholars-program-in-india-launches-at-iiit-hyderabad-302839774.html"},"analysis":{"id":"93654","press_release_id":"104640","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Amgen launched the first Amgen Scholars Program in India at IIIT Hyderabad, backed by a two-year commitment through summer 2027.\n\nThe inaugural cohort features 10 undergraduate students from Asia who will focus on artificial intelligence and machine learning applications in drug discovery and healthcare.\n\nParticipants will complete a two-month residential research experience and present their findings at a regional symposium in Tokyo in August 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Amgen expands education initiative to India to build AI-focused scientific talent."},"keyFigures":{"customDimensions":{"cohort_size":10,"program_duration_years":2}},"quotedText":"Scientific breakthroughs begin with curious minds and meaningful opportunities to learn","namedEntities":{"people":[{"name":"Naveen Gullapalli","role":"Managing Director, Amgen India"},{"name":"Deva Priyakumar","role":"Professor & Dean (R&D), IIIT Hyderabad"},{"name":"Sandeep Shukla","role":"Professor & Director, IIIT Hyderabad"}],"products":["Amgen Scholars Program"],"companies":[{"name":"Amgen","ticker":"AMGN"},{"name":"International Institute of Information Technology Hyderabad","relationship":"host institution"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Launch of a corporate social responsibility (CSR) education program. While beneficial for long-term talent pipeline and brand, it is not a material financial or operational event for a large-cap biotech."},"tickerRelevance":{"others":[],"primary":"AMGN"},"globalImportance":10,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"csr-education","sectorWeight":"health-care"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Amgen launched the first Amgen Scholars Program in India at IIIT Hyderabad, backed by a two-year commitment through summer 2027.\n\nThe inaugural cohort features 10 undergraduate students from Asia who will focus on artificial intelligence and machine learning applications in drug discovery and healthcare.\n\nParticipants will complete a two-month residential research experience and present their findings at a regional symposium in Tokyo in August 2026.","key_figures":{"customDimensions":{"cohort_size":10,"program_duration_years":2}},"named_entities":{"people":[{"name":"Naveen Gullapalli","role":"Managing Director, Amgen India"},{"name":"Deva Priyakumar","role":"Professor & Dean (R&D), IIIT Hyderabad"},{"name":"Sandeep Shukla","role":"Professor & Director, IIIT Hyderabad"}],"products":["Amgen Scholars Program"],"companies":[{"name":"Amgen","ticker":"AMGN"},{"name":"International Institute of Information Technology Hyderabad","relationship":"host institution"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-31T06:40:10.923Z","global_importance":10,"audience_relevance":20,"importance_components":{"tickerTier":"large-cap","eventGravity":"csr-education","sectorWeight":"health-care"}},"durationMs":160732,"modelName":"glm-4.7"}}